Fernández, J, Núñez, L, Costa, M, Torres, M, Horrillo, R, Afonso, N, Mestre, A, Del Arbol, LR, Villanueva, C, Paez, A, Arroyo, V. Safety and tolerability of long-term albumin treatment in patients with decompensated cirrhosis. JOURNAL OF HEPATOLOGY. 2024; 80DOI:. PMID:. IF:33.000(Q1/1D).

Alberch, PO, Soler, A, Téllez, L, Carrión, JA, Alvarado-Tapias, E, Ferrusquía, JA, Lens, S, Guerrero, A, Falgà, MA, Vizcarra, P, Orts, L, Perez, V, Shalaby, S, Baiges, A, Turon, F, García-Pagán, JC, García-Criado, MA, Hernández-Gea, V. Evaluation of portal hemodynamics after etiological factor removal and persistence of varices in patients with an HVPG <10 mmHg and NITs within the grey zone. JOURNAL OF HEPATOLOGY. 2024; 80DOI:. PMID:. IF:33.000(Q1/1D).

Garcia, MJ, Riestra, S, Amiot, A, Julsgaard, M, de la Filia, IG, Calafat, M, Aguas, M, de la Pena, L, Roig, C, Caballol, B, Casanova, MJ, Farkas, K, Boysen, T, Bujanda, L, Cuaran, C, Dobru, D, Fousekis, F, Gargallo-Puyuelo, CJ, Savarino, E, Calvet, X, Huguet, JM, Kupcinskas, L, López-Cardona, J, Raine, T, van Oostrom, J, Gisbert, JP, Chaparro, M. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study). ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2024; 59(10)DOI:10.1111/apt.17938. PMID:38445785. IF:6.700(Q1/1D).

Gómez-Labrador, C, Ricart, E, Iborra, M, Iglesias, E, Martín-Arranz, MD, de Castro, L, De Francisco, R, García-Alonso, FJ, Sanahuja, A, Gargallo-Puyuelo, CJ, Mesonero, F, Casanova, MJ, Mañosa, M, Rivero, M, Calvo, M, Sierra-Ausin, M, González-Muñoza, C, Calvet, X, García-López, S, Guardiola, J, García, LA, Márquez-Mosquera, L, Gutiérrez, A, Zabana, Y, Navarro-Llavat, M, Poyatos, RL, Piqueras, M, Torrealba, L, Bermejo, F, Ponferrada-Díaz, A, Pérez-Calle, JL, Barreiro-de Acosta, M, Tejido, C, Cabriada, JL, Marín-Jiménez, I, Roncero, O, Ber, Y, Fernández-Salazar, L, Aler, BC, Lucendo, AJ, Llaó, J, Bujanda, L, Villafranca, CM, Domènech, E, Chaparro, M, Gisbert, JP. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA. Pharmaceutics. 2024; 16(5)DOI:10.3390/pharmaceutics16050629. PMID:38794292. IF:5.500(Q1/1D).